About this trial
To study the effect of anti-inflammatory diet on clinical and biological outcomes in lupus
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients who meet the 2019 EULAR/ACR Classification Criteria for SLE
patients who are on Cellcept or Myfortic for at least 3 months prior to screening
patients with a score of ≥55 on the Patient Reported Outcomes Measurement Information System (PROMIS) Pain interference scale.
Disqualifiers
pregnant or lactating patients,
patients with food allergy
patients on antibiotics within 4 weeks of the screening
patients that change the SLE therapy during the length of the study (12 weeks).
Trial design
Single group
Treatments tested in this trial
anti-inflammatory diet
Dietary supplementanti-inflammatory diet for 6 weeks
Treatment groups
Trial outcomes
Primary outcomes
PROMIS pain interference
PROMIS Pain Interference: Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference. Scores are typically reported as T-scores ranging from approximately 20 to 80 (theoretical range varies by item bank). Higher scores indicate worse outcomes, reflecting greater pain interference with daily activities.
PROMIS fatigue
PROMIS Fatigue: Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue. Scores are typically reported as T-scores ranging from approximately 20 to 80. Higher scores indicate worse outcomes, reflecting greater fatigue.
Secondary outcomes
PROMIS physical function
PROMIS Physical Function: Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function. Scores are typically reported as T-scores ranging from approximately 20 to 80. Higher scores indicate better outcomes, reflecting better physical functioning.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.